BioInvent International ABBOVNF 53 Altman Z2-Score is 5.64 as of Jul. 01, 2026, which is 46% below its 10-year median of 10.45. GuruFocus rates BOVNF with a GF Score™ of 53/100 and a GF Value™ of $6.77. The stock has 4 warning signs investors should review. Among 1,394 Biotechnology companies, BioInvent International AB ranks better than 73.67% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
BioInvent International AB has a Altman Z2-Score of 5.64, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for BioInvent International AB's Altman Z2-Score or its related term are showing as below:
BOVNF'
s Altman Z2-Score Range Over the Past 10 Years
Min: -43.67 Med: 10.45 Max: 32.52
Current: 5.64
During the past 13 years, BioInvent International AB's highest Altman Z2-Score was 32.52. The lowest was -43.67. And the median was 10.45.
BioInvent International AB (OTCPK:BOVNF) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOVNF vs VRTX, REGN, ALNY: Altman Z2-Score Comparison
For the Biotechnology subindustry, BioInvent International AB's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB Altman Z2-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's Altman Z2-Score falls into.
BioInvent International AB Altman Z2-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
BioInvent International AB (BOVNF) has a Altman Z2-Score of 5.64 as of Jul. 01, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on BioInvent International AB and its competitors. This is 46% below median its historical median of 10.45. According to the industry distribution chart, BioInvent International AB ranks #367 out of 1394 companies in the Biotechnology industry, placing it in the top 26.3%.
Is BioInvent International AB's Altman Z2-Score too high?
BioInvent International AB's current Altman Z2-Score of 5.64 is 46% below median its 10-year median of 10.45. Based on the distribution chart, BioInvent International AB ranks #367 out of 1394 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioInvent International AB has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #367 out of 1394 companies for Altman Z2-Score. This puts BioInvent International AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Altman Z2-Score is 5.64, which is 46% below median its own 10-year median of 10.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current Altman Z2-Score of 5.64. The stock's GF Value™ is $6.77, compared to a current price of $3.29 — trading 51.4% below its estimated fair value. The current Altman Z2-Score is 5.64, which is 46% below median its 10-year median of 10.45. BioInvent International AB's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current Altman Z2-Score is 5.64 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (BOVNF) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of $3.29 is trading 51.4% below its estimated GF Value™ of $6.77.
Key valuation signals for BOVNF:
Altman Z2-Score: 5.64 (46% below median its 10-year median of 10.45)
GF Value™: $6.77 vs. price of $3.29 (51.4% below fair value)
No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
53GF Score
Get the complete analysis for BOVNF
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOVNF has been successfully added to your 
